Zimmer Biomet (NYSE:ZBH) had its target price boosted by analysts at Morgan Stanley from $140.00 to $150.00 in a research report issued to clients and investors on Monday. Morgan Stanley’s price objective would suggest a potential upside of 17.75% from the stock’s previous close.
ZBH has been the topic of several other research reports. Jefferies Group restated a “buy” rating and set a $136.00 target price on shares of Zimmer Biomet in a report on Friday, November 3rd. Stifel Nicolaus reiterated a “hold” rating and issued a $120.00 price target on shares of Zimmer Biomet in a report on Friday, November 3rd. SunTrust Banks reiterated a “buy” rating and issued a $136.00 price target on shares of Zimmer Biomet in a report on Monday, October 2nd. TheStreet cut Zimmer Biomet from a “b-” rating to a “c+” rating in a report on Friday, November 24th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Zimmer Biomet in a report on Friday, January 5th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $138.47.
Shares of Zimmer Biomet (NYSE ZBH) traded up $1.16 during mid-day trading on Monday, hitting $127.39. The stock had a trading volume of 2,540,000 shares, compared to its average volume of 1,430,000. The company has a quick ratio of 0.78, a current ratio of 1.47 and a debt-to-equity ratio of 0.88. The company has a market capitalization of $25,790.00, a PE ratio of 39.69, a PEG ratio of 1.97 and a beta of 1.15. Zimmer Biomet has a 12 month low of $108.03 and a 12 month high of $133.49.
Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 EPS for the quarter, missing the consensus estimate of $1.74 by ($0.02). The business had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.83 billion. Zimmer Biomet had a return on equity of 16.29% and a net margin of 8.36%. Zimmer Biomet’s revenue for the quarter was down .8% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.79 EPS. equities research analysts forecast that Zimmer Biomet will post 8.03 earnings per share for the current year.
A number of large investors have recently added to or reduced their stakes in the business. Meag Munich Ergo Kapitalanlagegesellschaft MBH acquired a new position in Zimmer Biomet in the fourth quarter valued at about $1,186,000. K.J. Harrison & Partners Inc lifted its stake in Zimmer Biomet by 41.3% in the fourth quarter. K.J. Harrison & Partners Inc now owns 12,720 shares of the medical equipment provider’s stock valued at $1,535,000 after buying an additional 3,720 shares during the period. Pillar Pacific Capital Management LLC lifted its stake in Zimmer Biomet by 1.6% in the fourth quarter. Pillar Pacific Capital Management LLC now owns 51,445 shares of the medical equipment provider’s stock valued at $6,208,000 after buying an additional 815 shares during the period. Eqis Capital Management Inc. acquired a new position in Zimmer Biomet in the fourth quarter valued at about $375,000. Finally, Robeco Institutional Asset Management B.V. lifted its stake in Zimmer Biomet by 113.2% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 5,120 shares of the medical equipment provider’s stock valued at $618,000 after buying an additional 2,718 shares during the period. 86.20% of the stock is currently owned by hedge funds and other institutional investors.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.